newsfilter
← Latest News
Business Wire·

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets